Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 7/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5024375 | 0.83 | NCF1 (0.67) | NCF1ADRB2ADRB1USP2LMNA | |
| SCHEMBL5026894 | 0.79 | NCF1 (0.48) | NCF1ADRB2ADRB1USP2LMNA | |
| SCHEMBL5026897 | 0.79 | NCF1 (0.48) | NCF1ADRB2ADRB1USP2LMNA | |
| SCHEMBL30511704 | 0.78 | NCF1 (0.97) | NCF1ADRB2ADRB1USP2LMNA | |
| Cyclopropane SCHEMBL5025453 | 0.77 | NCF1 (0.61) | NCF1ADRB2ADRB1MEN1KMT2A | |
| SCHEMBL5397410 | 0.76 | NCF1 (0.72) | NCF1ADRB2ADRB1USP2LMNA | |
| SCHEMBL5024412 | 0.76 | NCF1 (0.53) | NCF1ADRB2ADRB1USP2LMNA | |
| SCHEMBL5401181 | 0.75 | NCF1 (0.74) | NCF1ADRB2ADRB1USP2LMNA | |
| SCHEMBL5028620 | 0.75 | NCF1 (0.55) | NCF1ADRB2ADRB1USP2LMNA | |
| SCHEMBL5024607 | 0.75 | MAPK1 (0.55) | NCF1ADRB2ADRB1USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474145-B1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-04-23 | — | — | EP | disclosed |
| CN-1627945-A | Quinoline derivatives as NPY antagonists | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | CN | disclosed |
| EP-1474145-A1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-6696467-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030153553-A1 | Quinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | US | disclosed |
| WO-2003066055-A1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153553-A1 | Quinoline derivatives | NPY1R, NPY4R, GLP1R | NCF1 1858/4885ADRB2 519/4885ADRB1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.